EMAIL THIS PAGE TO A FRIEND

Luminescence : the journal of biological and chemical luminescence

A lab-on-a-chip device for analysis of amlodipine in biological fluids using peroxyoxalate chemiluminescence system.


PMID 24782430

Abstract

A highly sensitive, rapid and economical method for the determination of amlodipine (AM) in biological fluids was developed using a peroxyoxalate chemiluminescence (CL) system in a lab-on-a-chip device. Peroxyoxalate-CL is an indirect type of CL that allows the detection of native fluorophores or compounds derivatized with fluorescent labels. Here, fluorescamine was reacted with AM, and the derivatization product was used in a bis-(2,4,6-trichlorophenyl)oxalate-CL system. Fluorescamine reacts selectively with aliphatic primary amine at neutral or basic pH. As most of the calcium channel blocker and many cardiovascular drugs do not contain primary amine, the developed method is highly selective. The parameters that influenced the CL signal intensity were studied carefully. These included the chip geometry, pH, concentration of reagents used and flow rates. Moreover, we confirmed our previous observation about the effects of imidazole, which is commonly used in the bis-(2,4,6-trichlorophenyl)oxalate-CL system as a catalyst, and found that the signal was significantly improved when imidazole was absent. Under optimized conditions, a calibration curve was obtained with a linear range (10-100 µg/L). The limit of detection was 3 µg/L, while the limit of quantification was 10 µg/L. Finally the method was applied for the determination of AM in biological fluids successfully.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

75707
Bis(2,4,6-trichlorophenyl) oxalate, BioReagent, suitable for chemiluminescence, ≥99.0% (AT)
C14H4Cl6O4
H4759
Hydrochlorothiazide, crystalline
C7H8ClN3O4S2
H2910
Hydrochlorothiazide, meets USP testing specifications
C7H8ClN3O4S2
1314009
Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard
C7H8ClN3O4S2
PHR1032
Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material
C7H8ClN3O4S2
H1200000
Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
Y0001494
Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
71505
Sodium phosphate monobasic dihydrate, BioUltra, for molecular biology, ≥99.0% (T)
H2NaO4P · 2H2O
71502
Sodium phosphate monobasic dihydrate, BioUltra, ≥99.0% (T)
H2NaO4P · 2H2O
71500
Sodium phosphate monobasic dihydrate, purum p.a., crystallized, ≥99.0% (T)
H2NaO4P · 2H2O
04269
Sodium phosphate monobasic dihydrate, meets analytical specification of Ph. Eur., BP, USP, FCC, E 339, 98-100.5% (calc. to the dried substance)
H2NaO4P · 2H2O
Y0001132
Valsartan, European Pharmacopoeia (EP) Reference Standard
C24H29N5O3
1708762
Valsartan, United States Pharmacopeia (USP) Reference Standard
C24H29N5O3
PHR1315
Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material
C24H29N5O3
Y0001131
Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard
C24H29N5O3
Y0001145
Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard
C24H29N5O3